TMS (4891) Stock Overview
Engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
4891 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
TMS Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥132.00 |
| 52 Week High | JP¥314.00 |
| 52 Week Low | JP¥120.00 |
| Beta | 0.18 |
| 1 Month Change | -1.49% |
| 3 Month Change | -14.84% |
| 1 Year Change | -38.89% |
| 3 Year Change | -79.05% |
| 5 Year Change | n/a |
| Change since IPO | -82.83% |
Recent News & Updates
Shareholder Returns
| 4891 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 2.3% | -1.1% | 1.3% |
| 1Y | -38.9% | -10.4% | 25.5% |
Return vs Industry: 4891 underperformed the JP Biotechs industry which returned -12.7% over the past year.
Return vs Market: 4891 underperformed the JP Market which returned 22% over the past year.
Price Volatility
| 4891 volatility | |
|---|---|
| 4891 Average Weekly Movement | 4.7% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in JP Market | 8.0% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4891 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4891's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 18 | Takuro Wakabayashi | www.tms-japan.co.jp |
TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development.
TMS Co., Ltd. Fundamentals Summary
| 4891 fundamental statistics | |
|---|---|
| Market cap | JP¥6.00b |
| Earnings (TTM) | -JP¥670.00m |
| Revenue (TTM) | n/a |
Is 4891 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4891 income statement (TTM) | |
|---|---|
| Revenue | JP¥0 |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥0 |
| Other Expenses | JP¥670.00m |
| Earnings | -JP¥670.00m |
Last Reported Earnings
Aug 31, 2025
Next Earnings Date
Feb 13, 2026
| Earnings per share (EPS) | -14.73 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 4891 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/05 06:27 |
| End of Day Share Price | 2026/01/05 00:00 |
| Earnings | 2025/08/31 |
| Annual Earnings | 2025/02/28 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TMS Co., Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Miyabi Yamakita | Jefferies LLC |